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nostic modalities in the acute stem cell transplant period. A normal
CXR does not deﬁnitively exclude a pulmonary process in this
group of patients and additional CT evaluation should be consid-
ered, particularly in patients with pulmonary symptoms.
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FACTORS CONTRIBUTING TO VIRUSES REACTIVATION AND HEMOR-
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Polyomaviruses (HPV: BKV or JCV)–induced late-onset hem-
orrhagic cystitis (HC) is a signiﬁcant cause of morbidity after
hematopoietic stem cell transplantation (HSCT). However, issues
facilitating HPV reactivation and related HC remain unclear. The
aim of the study was to evaluate the incidence, risk factors and
clinical implications of BKV and JCV infection in children after
HSCT. One hundred forty two children (121 after allo- and 21
after auto-HSCT) were prospectively evaluated for BKV/JCV in-
fection and HC. Viral DNA was identiﬁed in plasma and urine
with qualitative PCR. The PCR products were cleft with the
enzyme BamH1 to discriminate between BKV and JCV sequences.
HC diagnosis was based on the clinical symptoms, the presence of
hematuria and USG of the bladder. Cumulative incidence (CI)
curves were created to assess the risk of BKV or JCV infection.
Multivariate analysis of potential risk factors of HPV reactivation
and HC among allografted patients (Age, gender, diagnosis, donor,
cell source, CMV reactivation, conditioning, GvHD and its pro-
phylaxis) was performed with Fine and Grey model. RESULTS:
HPV viruria was detected in 6 (28.5%) of 21 autografted patients,
in 5 BKV (23.8%) and 1 JCV (4.8%), only 1 patient developed HC.
No HPV viremia was observed. Following allo-HSCT, HPV were
found in 65 (53,7%) children. BKV viruria was detected in 60
(49,5%) and was accompanied by BKV viremia in 15 patients. JCV
viruria was discovered in 4 (3.3%) children with concomitant JCV
viremia in 1 patient. In 1 child (0.8%) parallel BKV and JCV
viremia and viruria were found. The CI of HPV viruria was higher
among children after allo-HSCT, however the difference was in-
signiﬁcant (p0.07). In univariate analysis, the following signiﬁ-
cant risk factors of HPV viruria were identiﬁed: age 10 years,
HSCT from MUD and ATG in the conditioning. In multivariate
analysis age remained the only signiﬁcant. Multivariate analysis of
potential risk factors of HC in children with HPV viruria revealed
that HPV viremia and chemotherapy-based conditioning increased
the risk signiﬁcantly, while TBI appeared to do the opposite.
CONCLUSIONS: BKV viruria is common in children after allo-
HSCT. The risk of HPV shedding increases with age and this
indirectly indicates reactivation rather than de novo infection. HC
after allo-HSCT is induced by HPV in conjunction with viremia
and chemotherapy-based conditioning. However, the role of addi-
tional factors can not be excluded.
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Limited data on sirolimus (SRL) in adult BMT patients is con-
sistent with a long elimination half-life (t1/2; 57-63 h) and little
effect of an occasional missed dose on overall drug exposure.
Pharmacokinetic (PK) studies in pediatric organ transplant recip-
ients suggest that SRL may be metabolized more rapidly in chil-
dren. BMT patients may have variable SRL exposure due to gas-
trointestinal toxicity, and interactions with calcineurin inhibitors
and imidazole antifungaldrugs.
SRL PK proﬁles were evaluated in 19 pediatric BMT recipients
with high-risk ALL treated on a pilot trial using SRL-based
GVHD prophylaxis. Mean age at transplant was 11 y (4-21 y); 13
males, 6 females; 14 Whites, 4 Hispanic, 1 Black. Stem cell source:
12 unrelated cord blood, 6 sibling bone marrow, and 1 unrelated
PBSC. Preparative regimen: TBI 1200 cGy, thiotepa 10mg/kg,
and cyclophosphamide 120mg/kg. GVHD prophylaxis: continuous
infusion tacrolimus from day -2, IV methotrexate (5mg/m2, 4-5
doses) and oral SRL (2.5 mg/m2/d; 4mg/d max) from day -2 (1),
day -1 (1), day 0 (16), and day 1 (1). Out of 119 SRL doses, 14 were
followed by emesis, and 10 of these were redosed. Sixteen patients
also received ﬂuconazole prophylaxis.
Timed multiple blood samples (8-9) were drawn after sixth (14),
seventh (5), or eighth (1) dose of SRL. Whole blood SRL concen-
trations were measured by liquid chromatography with tandem-
mass spectrometry. Mean SRL dose was 2.6 mg/day (1-4 ); 2.3
mg/day/m2 (1.1-4). In 20 PK studies, SRL concentrations normal-
ized to dose (mean	SD, ng/mL/mg) were: trough level before the
dose (C0) 3.50	2.40, maximum (Cmax) 6.74	5.37, and 24 hours
later (C24) 3.29	2.38. C0 and C24 were similar and correlated well
(r2  0.905), indicating achievement of steady state. SRL dose did
not correlate with AUC (r2  0.12), while C0 and C24 correlated
well with AUC (r2 0.918; 0.929, respectively). SRL apparent oral
clearance was 4.1	4.5 ml/min/kg (0.87–20) and t1/2 25	13 h (9-71
h). SRL t1/2 in our patient group were markedly lower than those
reported in adults, and comparable to those observed in pediatric
liver and small bowel transplant recipients on tacrolimus and SRL
(19.3 to 21.2 h). In conclusion, we show that GVHD prophylaxis
with SRL is feasible even in young children, and PK data supports
24 h dosing interval; wide individual variability and lack of corre-
lation of dose with AUC supports the need for SRL therapeutic
monitoring and dose adjustments based on steady state blood
levels.
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Sinusoidal Obstruction Syndrome (SOS) is characterized by en-
dothelial cell damage in the liver and associated with signiﬁcant
morbidity and mortality. It is a well documented complication of
abdominal irradiation, speciﬁc chemotherapeutic agents, monoclo-
nal antibodies and hematopoietic stem cell transplant (HSCT).
Deﬁbrotide is an experimental polydeoxyribonucleotide agent with
liver endothelial cell activity that has clinically encouraging results
in the treatment of SOS. In this study, we report a single institution
retrospective analysis of the efﬁcacy of deﬁbrotide in treating SOS
in a post-HSCT pediatric population. A total of 11 patients were
treated with deﬁbrotide after being clinically diagnosed with severe
SOS having a 30% likelihood of mortality based on the Bearman
model of life expectancy. The protocol was IRB approved and each
patient was individually assigned an FDA IND number prior to
treatment. All patients had received ursodiol for SOS prophylaxis.
Seven of 11 patients received TBI-based conditioning and 4 pa-
tients received ablative chemotherapy alone. The median age was
6.6 years at time of treatment (range, 5 months to 18 yrs). All
patients were Caucasian, with 4 males and 7 females. The stem cell
source was unrelated cord blood in 4 patients, unrelated bone
marrow in 2, autologous peripheral blood in 2, and related bone
marrow in 3. Engraftment (ANC 500) occurred on average 23.2
days post-SCT (mean: Cord  30 days, BM  22.6 days, autolo-
gous  11 days). 10 of 11 patients had primary malignancies
(AML, ALL, neuroblastoma, pineoblastoma) while 1 patient had
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